CMS has advised Autolus Ltd, a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies, on its $80m series C financing.
New investors Cormorant Asset Management, Nextech Invest and others joined founding investor Syncona, Woodford Investment Management and Arix Bioscience in the series C round. The funds will enable Autolus to establish clinical proof of concept for three programs: AUTO2 in multiple myeloma, AUTO3 in diffuse large B cell lymphoma and paediatric acute lymphoblastic leukaemia and AUTO4 in T-cell lymphoma. In addition, building on its advanced cell programming technologies Autolus plans to advance its pre-clinical pipeline products for solid tumour indications, and will set-up the infrastructure required for bringing a CAR-T cell therapy rapidly and successfully to market.
The CMS team was led by Partner Simon Morgan, with support from Senior Associate Theo Godfrey and Associate Jennifer Lloyd.
Simon Morgan commented, "CMS is a proud supporter of biopharmaceutical businesses. We are delighted to have helped our client Autolus secure this funding to support the development and commercialisation of its innovative products.”